Zhouxiao Li

1.8k total citations · 2 hit papers
45 papers, 1.1k citations indexed

About

Zhouxiao Li is a scholar working on Surgery, Molecular Biology and Oncology. According to data from OpenAlex, Zhouxiao Li has authored 45 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Surgery, 15 papers in Molecular Biology and 13 papers in Oncology. Recurrent topics in Zhouxiao Li's work include Cancer-related molecular mechanisms research (6 papers), Cancer Immunotherapy and Biomarkers (6 papers) and Circular RNAs in diseases (6 papers). Zhouxiao Li is often cited by papers focused on Cancer-related molecular mechanisms research (6 papers), Cancer Immunotherapy and Biomarkers (6 papers) and Circular RNAs in diseases (6 papers). Zhouxiao Li collaborates with scholars based in China, Germany and United States. Zhouxiao Li's co-authors include Weiwei Tang, Hongyong Cao, Dawei Rong, Handong Sun, Kai Fu, Shuheng Liu, Riccardo E. Giunta, Konstantin Christoph Koban, Thilo L. Schenck and Yangbai Sun and has published in prestigious journals such as Physical Chemistry Chemical Physics, Annals of Oncology and Trends in Pharmacological Sciences.

In The Last Decade

Zhouxiao Li

38 papers receiving 1.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

An emerging function of circRNA-miRNAs-mRNA axis in human diseases

2017 399 citations Zhouxiao Li, Weiwei Tang et al. profile →
Artificial Intelligence in Dermatology Image Analysis: Current Developments and Future Trends

2022 117 citations Zhouxiao Li, Konstantin Christoph Koban et al. Journal of Clinical Medicine profile →

Peers

Countries citing papers authored by Zhouxiao Li

Since Specialization

Citations

This map shows the geographic impact of Zhouxiao Li's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Zhouxiao Li with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Zhouxiao Li more than expected).

Fields of papers citing papers by Zhouxiao Li

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Zhouxiao Li. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Zhouxiao Li. The network helps show where Zhouxiao Li may publish in the future.

Co-authorship network of co-authors of Zhouxiao Li

This figure shows the co-authorship network connecting the top 25 collaborators of Zhouxiao Li. A scholar is included among the top collaborators of Zhouxiao Li based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Zhouxiao Li. Zhouxiao Li is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	LBA14 Adjuvant ribociclib (RIB) plus nonsteroidal aromatase inhibitor (NSAI) in patients (pts) with HR+/HER2− early breast cancer (EBC): NATALEE 5-year outcomes 2025 ·Annals of Oncology ·(unknown), Daniil Stroyakovskiy, DA Yardley, Chiun‐Sheng Huang, Peter A. Fasching, Amit Bardia, (unknown), S-A Im, Miguel Martín, B. Xu, Carlos H. Barrios, (unknown), R Moroose, (unknown), Gabriel N. Hortobágyi, (unknown), F. Visco, Gonzalo Spera, Zhouxiao Li, Sherene Loi	0
2	Metabolic Reprogramming in Urological Tumors: New Perspectives from Tumor Metabolic Phenotypes to Therapeutic Targets 2025 ·International Journal of Biological Sciences ·Zhuohang Li, Lin Yang, Weijia Li, Wenxue Huang, (unknown), (unknown), Xi Yang, (unknown), Zhouxiao Li, J. Zhao, (unknown), Peng Wu	0
3	An experimental and theoretical study of the photoionization properties of polysulfanes (H₂S_n, n = 2–4) 2025 ·Physical Chemistry Chemical Physics ·Zhouxiao Li, Shuicheng Yan, Xuedong Gong, Wei‐Jun Zheng, Chongqin Zhu, Cheng Zhu	1
4	Multi-satellite mission allocation and scheduling method for large-scale problem 2025 ·Advances in Space Research ·Zhouxiao Li, Yuan Liu, (unknown), (unknown)	0
5	Gr-1 blockade remodels the immunosuppressive microenvironment induced by incomplete microwave ablation of hepatocellular carcinoma 2024 ·Cancer Cell International ·(unknown), (unknown), Shipeng Dai, Yonghua Zhu, (unknown), (unknown), (unknown), Chuan Liu, (unknown), Zhouxiao Li, Jinhua Song, Han Zhuo	3
6	Advances in GPCR-targeted drug development in dermatology 2024 ·Trends in Pharmacological Sciences ·(unknown), (unknown), (unknown), Zhouxiao Li, Danru Wang, Qingfeng Li, Chao Zhang	2
7	113MO NATALEE update: Safety and treatment (tx) duration of ribociclib (RIB) + nonsteroidal aromatase inhibitor (NSAI) in patients (pts) with HR+/HER2− early breast cancer (EBC) 2024 ·ESMO Open ·Carlos H. Barrios, Nadia Harbeck, Gabriel N. Hortobágyi, J. O’Shaughnessy, Chiun‐Sheng Huang, M. Martín Jiménez, (unknown), Barbara Pistilli, Baojun Xu, Michelino De Laurentiis, (unknown), Karen Afenjar, Eva Sum, Zhouxiao Li, (unknown), (unknown), (unknown)	2
8	GJB2 Promotes HCC Progression by Activating Glycolysis Through Cytoplasmic Translocation and Generating a Suppressive Tumor Microenvironment Based on Single Cell RNA Sequencing 2024 ·Advanced Science ·(unknown), Xiao Li, (unknown), Xiaopei Hao, (unknown), Yuliang Wang, Hao Zhuang, (unknown), Tian Huang, Chuan Liu, (unknown), (unknown), (unknown), Li Liu, Hanjin Wang, Zhouxiao Li, Weiwei Tang	10
9	Extracellular RNA in melanoma: Advances, challenges, and opportunities 2023 ·Frontiers in Cell and Developmental Biology ·Zhouxiao Li, (unknown), Yang Cao, (unknown), (unknown), Hanyuan Liu, Hongzhou Cai, Tao Zan	6
10	Inhibition of PARP Potentiates Immune Checkpoint Therapy through miR-513/PD-L1 Pathway in Hepatocellular Carcinoma 2022 ·Journal of Oncology ·Guoqiang Sun, (unknown), Zhitao Li, (unknown), Chunguang Zhou, Guangshun Sun, Hongyong Cao, Zhouxiao Li, Weiwei Tang	11
11	Nonsubjective Assessment of Shape, Volume and Symmetry during Breast Augmentation with Handheld 3D Device 2022 ·Journal of Clinical Medicine ·Zhouxiao Li, Thilo L. Schenck, Riccardo E. Giunta, (unknown), Konstantin Christoph Koban	0
12	Tegaserod Maleate Inhibits Breast Cancer Progression and Enhances the Sensitivity of Immunotherapy 2022 ·Journal of Oncology ·Xiao Li, Liangliang Wu, Zhiying Zheng, Hanyuan Liu, Haiyang Li, Guoqiang Sun, Guangshun Sun, Ye Cheng, Hanjin Wang, Zhouxiao Li, Junfeng Shi, Weiwei Tang	4
13	Objective evaluation of volumetric changes during breast augmentation using intraoperative three-dimensional surface imaging 2022 ·Journal of Plastic Reconstructive & Aesthetic Surgery ·Konstantin Christoph Koban, Zhouxiao Li, (unknown), Thilo L. Schenck, (unknown), Riccardo E. Giunta	0
14	Artificial Intelligence in Dermatology Image Analysis: Current Developments and Future Trends breakdown → 2022 ·Journal of Clinical Medicine ·Zhouxiao Li, Konstantin Christoph Koban, Thilo L. Schenck, Riccardo E. Giunta, Qingfeng Li, Yangbai Sun	117
15	143P Efficacy and safety of the anti-PD-L1 monoclonal antibody Socazolimab in combination with carboplatin and etoposide for extensive-stage small cell lung cancer: Results from the phase Ib clinical trial 2022 ·Annals of Oncology ·Sheng Lu, (unknown), Zhouxiao Li, Zhuochao Zhou, (unknown), (unknown), Yizhou Zhao, Xiaoyin Niu, Jianli Cui, Renhua Guo, (unknown), Xiangrong Dai, (unknown), (unknown), (unknown), (unknown)	2
16	Comprehensive Analysis of VCAN Expression Profiles and Prognostic Values in HCC 2022 ·Frontiers in Genetics ·Guangshun Sun, Wubin Zheng, (unknown), Jin Zhou, Weiwei Tang, Hongyong Cao, Li Liu, Xuesong Shi, Zhouxiao Li, Wenling Zhang	3
17	Upregulation of ADAR Promotes Breast Cancer Progression and Serves as a Potential Therapeutic Target 2021 ·Journal of Oncology ·Xiao Li, Guangshun Sun, Liangliang Wu, (unknown), Ye Cheng, (unknown), Zhouxiao Li, Weiwei Tang, Hanjin Wang	12
18	Digital Leg Volume Quantification: Precision Assessment of a Novel Workflow Based on Single Capture Three-dimensional Whole-Body Surface Imaging 2021 ·Journal of Digital Imaging ·(unknown), Thilo L. Schenck, Riccardo E. Giunta, Zhouxiao Li, (unknown), Konstantin Christoph Koban	0
19	127P A prospective phase II clinical trial exploring neoadjuvant immunotherapy combined with chemotherapy in resectable thoracic esophageal squamous cell cancer (TESCC) with multi-station lymph node metastases (NICE study): Preliminary results 2020 ·Annals of Oncology ·(unknown), Zhouxiao Li, Xiaolong Fu, Ying Yang, (unknown), Yanjie Chen	11
20	LBA8_PR Pembrolizumab plus chemotherapy versus chemotherapy as first-line therapy in patients with advanced esophageal cancer: The phase 3 KEYNOTE-590 study 2020 ·Annals of Oncology ·Ken Kato, (unknown), Manan Shah, Peter C. Enzinger, Antoine Adenis, Toshihiko Doi, Takashi Kojima, J-P. Metges, Zhouxiao Li, S-B. Kim, (unknown), Wasat Mansoor, SH Li, Patrapim Sunpaweravong, María Maqueda, Eray Goekkurt, (unknown), Sukrut Shah, Pooja Bhagia, Lin Shen	98

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact